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Abstract 
Tuberculosis (TB) treatment, based on the use of isoniazid (INH), rifampicin (RMP) and pyrazinamide (PZA), 
shown to cause drug-induced hepatotoxicity (DIH). Recent studies have demonstrated that genetic variations 
may associate with the risk of DIH, such as INH acetylation status, related to N-acetyl transferase (NAT) 2 
polymorphism, which slow acetylation are more prone to side effects from drugs. The proportion of rapid and 
slow acetylator vary remarkably in populations of different ethnic or geographic origin which has been 
described in the various study, but, there is still limited information on our population. The objective of this 
study is to investigate the contribution of NAT2 polymorphisms to the anti-TB DIH in our population. This 
case-control study conducted at the Cipto Mangunkusumo Hospital, Jakarta and Omni Hospital Alam Sutera, 
Tangerang, Indonesia from January 2015  -  December 2016. We recruited 38 patients with DIH and 37 patients 
without DIH. A complete liver function profile, total serum bilirubin, indirect bilirubin and direct bilirubin were 
measured. Polymorphisms NAT2*5, *6 and *7 were selected to perform genotyping with the representative SNP 
are respectively rs1799929, rs1799930 and rs1799931.  
------------------------------------------------------------------------ 
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Results of this study showed that 10.67% (8/75) of the subjects were NAT2 mutant homozygotes. There is a 
statistical difference in acetylator status between slow and rapid acetylator with OR for NAT2 slow acetylators 
compared with rapid acetylators was 4.183 (95% CI 1.416 – 12.354, P = 0.007). In a subanalysis, between slow 
acetylator polymorphism, NAT2*6 have been shown to predominate the risk for DIH, as shown in other Asian 
populations.  In conclusion, slow acetylator status of NAT2 was a significant susceptibility risk factor for anti-
TB DIH in Indonesia.  
Keywords: TB; NAT2; Polymorphisms; slow acetylators; drug-induced hepatotoxicity. 
1. Introduction  
Drug-induced hepatotoxicity (DIH) is defined as a significant abnormality in liver function test (LFT), with an 
elevation of serum aminotransferases or bilirubin, along with clinical features such as anorexia, nausea, 
vomiting and jaundice during treatment [1].  Its spectrum ranges from hepatic adaptation to severe 
hepatotoxicity. Hepatic adaptation is a physiological phenomenon whereby the activation of various 
constitutional genes helps in averting drug- or toxin-related injury. It manifests as asymptomatic transient 
elevations of transaminases, and with persisting insult, may lead to hepatocellular injury [2]. The pathogenesis 
of DIH caused by these offending drugs is still enigmatic, and various mechanisms have been postulated.  
Tuberculosis (TB) treatment, based on the use of isoniazid (INH), rifampicin (RMP) and pyrazinamide (PZA), 
shown to cause adverse drug reaction (ADRs). One of the most serious ADRs is DIH, associated with high 
morbidity and mortality, as well as with increased treatment costs [3]. Other ADRs are gastrointestinal 
intolerance, kidney failure and cutaneous and hematological reaction which can lead to therapy discontinuation 
or more severe morbidity and mortality [4]. The interval between the start of anti-TB and the appearance of DIH 
varied from 1 week to 12 months, with the median being around eight weeks. Recovery usually occurs if drugs 
withdrawn before a severe liver injury happens [5]. 
The incidence of anti-TB DIH ranges from 1% to 36% [6].  A meta-analysis by Steele and his colleagues 
revealed a higher incidence of hepatotoxicity with concurrent administration of INH and RMP than with RMP 
or INH alone [7].  It has speculated that this is due to a drug to drug interaction in which induction of hepatic 
microsomal enzymes by RMP results in the production of increased concentration of a hepatotoxic metabolic 
product of INH.  Thus, increased plasma RMP levels may occur due to the displacement of the drug from 
plasma protein binding sites by INH.  This pharmacokinetic interaction between the two drugs may explain their 
added toxicity [7].  
Advanced age, female gender, alcoholism, malnutrition, co-infection with Human Immunodeficiency Virus 
(HIV), pre-existent liver disease and drug interactions are common risk factors for DIH [8]. Recent studies have 
demonstrated that genetic variations may associate with the risk of DIH [5]. Among them, genetic 
polymorphism in the drug-metabolizing enzyme (DME) genes, such as INH acetylator status, is also an 
important factor that predisposes certain fraction of the population to DIH [9].    
In the liver, INH is first metabolized into acetyl-isoniazid via N-acetyltransferase 2 (NAT2),  followed by 
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hydrolysis to acetyl hydrazine.  Acetyl hydrazine further oxidized into hepatotoxic intermediates by cytochrome 
P450 2E1 (CYP2E1) [10].  Direct hydrolysis of INH also generates hydrazine, a potent hepatotoxin. Disposal of 
acetyl hydrazine also depends on further acetylation by NAT2 to form a non-toxic metabolite, diacetyl 
hydrazine. Glutathione S-transferase (GSTs) are detoxification enzymes that catalyze the conjugation of 
glutathione to several classes of molecules including toxic intermediates of the INH metabolism [11].   
N-acetyltransferase 2 is located on chromosome 8p21.3 – 23.1 [3].  It refers to inter-individual differences in the 
acetylation capacity. Two main metabolic phenotypes have been described in human populations: the fast 
acetylator phenotype, association with a normal acetylators capacity, and the slow acetylator phenotype 
characterized by a decreased enzyme activity. Slow acetylators are more prone to side effects from drugs that 
are acetylated, due to the build-up of non-metabolized drugs [12, 13]. On the contrary, fast acetylators may 
exhibit therapeutic failure after standard doses [14].  
 The proportion of rapid and slow acetylators vary remarkably in populations of different ethnic or geographic 
origin. Therefore, routine screening of individuals for their acetylator status before initiation of therapy should 
permit to improve drug efficacy and reduce adverse events [14]. Genotyping is accepted as an accurate and 
efficient means to determine acetylator status since a high correlation between phenotype and genotype has been 
demonstrated in several studies [14].  Over 65 NAT2 variants possessing one or more SNPs in the 870-bp NAT2 
coding region have been reported. The seven most frequent SNPs are rs1801279 (191G>A), rs1041983 
(282C>T), rs1801280 (341T>A), rs1799929 (481C>T), rs1799930 (590G>A), rs1208 (803A>G) and rs1799931 
(857G>A) [15].  The analysis of the seven most common SNPs in NAT2 as described above has been shown to 
be highly predictive of the acetylator phenotype with a prediction rate close to 100% [14].  Because of the high 
cost and several days are necessary to complete the analysis,  the majority of studies investigate the NAT2 
genotype assay for three SNPs: 481C>T, 590 G>A and 857 G>A [15].  Based on Sabbagh and Darlu on SNP 
selection at the NAT2 locus for an accurate prediction of the acetylation phenotype in Koreans with tree-based 
analysis, neural network analysis and multifactor dimensionality reduction analysis; combination of 341T>C, 
590G>A and 857G>A had 100% accuracy for predicting acetylation phenotype compared with  seven most 
common SNPs [14]. 
A relationship between gene polymorphisms and anti-TB DIH has been described in the various study, there is 
still limited information in our population, which has a heterogeneous genetic background. The objective of the 
present study is to investigate the contribution of NAT2 variants to the anti-TB DIH.  
2. Materials and Method 
2.1. Collection of Samples 
The present study was carried out at the Cipto Mangunkusumo Hospital, Jakarta and Omni Hospital Alam 
Sutera, Tangerang, Indonesia from January 2015  to December 2016. All patients presenting to the clinic who 
fulfilled the inclusion/exclusion criteria were recruited. From this sample, we selected 38 patients with DIH and 
37 patients without DIH. Study subjects were 15 – 70 years old, newly diagnosed with active TB, with lesions 
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of TB clearly visible on chest X-ray, or positive sputum smear. Patients who developed DIH were classified as 
cases, while the remainder were classified as controls. Drug-induced hepatotoxicity was defined according to 
the criteria established by the Council for International Organizations of Medical Sciences (CIOMS) as an 
increase in liver biochemical parameters more than two times the upper limit of normal occurring at any time 
during anti-TB treatment [6, 16].  The upper limit of generally used in the study was 31 IU/mL for serum 
alanine transferase (ALT), 32 IU/mL for serum aspartate transferase (AST) and 1.1 mg/dL for total bilirubin. 
Subjects excluded if fulfill the following criteria;  Abnormal serum ALT, AST or bilirubin levels or symptoms 
related to abnormal liver function, such as jaundice, before anti-TB treatment.  Alcohol- related liver disease or 
habitual alcohol drinking if daily consumption is more than 40 gr for at least five years [17]. Any other hepatic 
or systemic diseases that may cause liver dysfunction, such as carriers of the hepatic B or C virus, heart failure, 
respiratory failure, HIV infection, etc.. Concomitant use of hepatotoxic drugs.  Pregnant women at the time of 
DIH.  Each individual agreed to participate in the study by signing an informed consent and recruited as 
samples. 
2.2. Study design 
In this case controlled study, the following data were recorded in the beginning of the study: demographics, 
nutritional status (body mass index [BMI]), duration of DIH occured and data on ALT, AST and bilirubin level. 
All patients enrolled in the study received a daily anti-TB regimen: INH 300 mg, RMP 600 mg (or 450 mg if 
body weight was < 50 kg), PZA 200 mg/kg body weight and EMT 800 mg daily for first 2 months. Patients 
blood sample were collected at the beginning of the study.  A complete liver function profile including serum 
aminotransferases, serum total bilirubin, indirect bilirubin and direct bilirubin were measured using routine 
laboratory methods to defined DIH.  
2.3. Polymorphism analysis 
Genomic DNA was extracted from 6 mL EDTA-anticoagulant peripheral whole blood sample using the DNA 
isolation kit from Taqman® Sample to SNP™ kit (Applied Biosystems®). Following the manufacturer’s 
instruction and was stored at -70oC until used for genotyping, which was carried out by Prodia Laboratory, 
Jakarta. In this study, polymorphisms NAT2*5, *6 and *7 were selected to perform genotyping.  The 
representative SNP are respectively rs1799929, rs1799930 and rs1799931.  All SNP genotyping was performed 
using the TaqMan® SNP genotyping assays (Applied Biosystems Inc, Foster City, CA, USA). Reactions were 
carried out according to the manufacturer’s protocol (Taqman SNP Genotyping Assays, protocol, part number 
4332856 Rev C). Probe fluorescence signal detection was performed using the CFX96 (Bio-Rad Laboratories 
Inc., Hercules, CA, USA) real-time polymerase chain reaction (rt-PCR) system.  
Interpretation for NAT2 allele haplotype based on http://nat.mbg.duth.gr/Human%20 
NAT2%20alleles_2013.htm (last updated on April 18, 2016). The NAT2 alleles classified on the grounds of the 
current knowledge of the functional impact of the variant alleles. Consequently, the NAT2*4 alleles considered 
as functional alleles and the NAT2*5, *6 and *7 alleles as slow alleles. Individuals homozygous for rapid NAT2 
acetylator alleles or heterozygous (one rapid and one slow NAT2 allele) were classified as rapid acetylators, 
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while those individuals homozygous for slow acetylator allele were considered slow acetylators [5, 14]. 
2.4. Statistical analysis 
The Kolmogorov-Smirnov test was used to assess whether data were normally or non-normally distributed. 
Accordingly, the mean ± Standard Deviation (SD) or median and Inter Quartile Range (IQR) used in the 
descriptive statistics. Categorical variables were compared by chi-square or Fischer’s exact test as necessary, 
and continuous variables were compared using Student’s t-test or Mann-Whitney test. Odds ratio (OR) and 95% 
confidence intervals (95% CI) calculated. All statistical analyses performed with SPSS v 22 (Chicago, IL, 
USA). Statistical significance was considered at p <0.05.  
2.5. Ethical Clearance 
Ethical approval for this study obtained from Research Ethics Committee, Mochtar Riady Institute for 
Nanotechnology Ethics Commitee (MRIN EC), Tangerang, West Java,  Indonesia. No. : 005/MRIN-
EC/0l/2015. Protocol no. : 04.1501023 
3. Results 
Characterisation of subjects 
Seventy-five subjects diagnosed with TB. Among them, 38 diagnosed with DIH. There was no statistical 
difference in gender (P = 0.131) and nutrition status based on BMI (P = 0.408) between subjects with and those 
without anti-TB DIH.  
Table 1: Characteristics of subjects with or without antituberculosis drug-induced hepatotoxicity 
Parameter Case (n=38) Control (n=37) p- value 
Gender, n(%)    
        Male 12 (31.6) 18 (48.6) 
0.131a        Female 26 (68.4) 19 (51.4) 
Age, n(%)     
      < 45 years old 18 (47.4) 28 (75.7) 
0.012a       ≥ 45 years old 20 (52.6) 9 (24.3) 
Body Mass Index    
      < 18.5 kg/m2 10 (26.3) 13 (35.1) 
0.408a       ≥ 18.5 kg/m
2 28 (73.7) 24 (64.9) 
AST (U/mL)  251.5 (11-898) 19 (9-79) < 0.001b 
ALP (U/ml) 205.5 (14-686) 14 (4-59) < 0.001b 
          a Chi Square test; b Mann Whitney            AST: aspartate transaminase; ALP: alanine transaminase 
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A significant difference found between age group (p = 0.012) and transaminases level (p < 0.001)  between 
subjects with and without  DIH.  
Table 2: N-acetyl transferase two genotype frequencies in subjects with and without antituberculosis drug-
induced hepatotoxicity 
Polymorphism SNP id Allele Case (n) Control (n) p value 
  1/2* 11/12/22 11/12/22  
NAT2*4   4 7  
NAT2*5 Rs1799929 C>T 30/7/1 29/8/0 0.586 
NAT2*6 Rs1799930 G>A 16/16/6 22/15/0 0.031* 
NAT2*7 Rs1799931 G>A 24/13/1 25/12/0 0.592 
1- allele 1, 2 – allele 2;  11 – homozygous for allele 1; 12 – heterozygous;  22 – homozygous for allele 2 
NAT2: N-acetyltransferase 2; SNP: single nucleotide polymorphism 
In this study, Table 2 showed that 10,67% (8/75) of the subjects were NAT2 mutant homozygotes. The allele 
frequency of NAT2*4 in the whole subjects was 14,67% (11/75); it was 10.53% (4/38) in the case group and 
18.91% (7/37) in the control group. 
Table 3: N-acetyl transferase two  rapid acetylator and slow acetylator genotypes and susceptibility to anti-
tuberculosis drug–induced hepatotoxicity 
 Case (n = 38) 
n (%) 
Control (n=37) 
n (%) OR (95% CI) 
Rapid acetylators 21 (37.5) 35 (62.5) 1 (reference) 
     NAT2*4/*4 4 11  
     NAT2*4/*5 2 5  
     NAT2*4/*6 9 10  
     NAT2*4/*7 6 9  
Slow acetylators 17 (73.9) 6 (26) 4.183 
(1.416 – 12.354)*      NAT2*5/*5 1 0 
     NAT2*5/*6 2 2  
     NAT2*5/*7 3 1  
     NAT2*6/*6 6 0  
     NAT2*6/*7 4 3  
     NAT2*7/*7 1 0  
      * p-value = 0.007 
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Our results showed that there is statistical difference in acetylator status between slow and rapid acetyltor with 
OR for NAT2 slow acetylators compared with rapid acetylators was 4.183 (95% CI 1.416 – 12.354, p = 0.007).  
4. Discussion 
Our results showed that there were significantly different between NAT2 slow and rapid acetylators which the 
slow acetylator groups were found more prone to the anti-TB DIH.  This result also performed on meta-analysis 
about NAT2 polymorphisms and susceptibility to anti-TB DIH conducted by Wang PY and his colleagues with 
OR 4.967 (95% CI 3.291 – 6.705, P < 0.001) and Lee SW and his colleagues with OR 3.28 [95% CI 1.53-7.06) 
[3, 18]. Consistently, slow acetylators have associated with an increased risk of hepatotoxicity during INH 
treatment with ORs ranging between 2.6 – 4 [19, 20].  As a matter of fact, in slow acetylators the overall amount 
of the INH moiety that is available for direct hydrolysis to hydrazine is larger than that available in rapid 
acetylators [21].  Kinzing-Schippers MD, and his colleagues found that INH plasma concentration is higher (up 
to six-fold at the short interval) in those individuals with low activity alleles of  NAT2 [22]. Among the slow 
acetylator polymorphisms in our study, NAT2*6 have been shown to predominate the risk for DIH, as shown in 
other Asian populations.  Since the Chinese, Japanese, Korean and Thai populations show comparable NAT2 
allele frequencies.  This finding is also likely to hold in other populations along the Pacific Asian littoral.  But, 
the most informative subset of SNPs for the prediction of acetylation phenotype in one population may not 
necessarily perform well in another if the population is sufficiently differentiated [14].  Some of the other 
environmental parameters which also been assessed in our study had various results. Gender was reported not 
affecting the incidence of DIH as shown in our study.  But Xiang and his colleagues (2014) on Uyghur China 
population found that incidence of DIH was higher among men than women [23]. Some other studies have 
shown that women are at an increased risk of developing DIH during treatment [24], but most studies did not 
find an association with gender [18, 25].  Low nutritional status is considered to be one of the factors 
contributing to the relatively high incidence of DIH in studies from the developing countries [17].  But in our 
study, we found no correlation between BMI < 18.5 kg/m2 and ≥ 18.5 kg/m2. In our study, the following 
baseline clinical factors were significantly associated with anti-TB DIH: advanced age group, AST, and ALT. 
The same results were also shown by Mushiroda and his colleagues (2016) also demonstrated that in the logistic 
regression analysis of all factors significantly associated with anti-TB DIH, age was identified as independent 
predictors of the risk of anti-TB DIH [26]. Genotyping of NAT2 was proven to be helpful in predicting 
hepatotoxicity risk in clinical practice, and modification of INH dosage based on NAT2 genotyping was 
effective in reducing the incidence of hepatotoxicity [27].  Azuma and his colleagues also shown a great 
potential of the NAT2 genotype-guided dosing stratification of INH in a randomized controlled trial for 
pharmacogenetic-based therapy [28]. Monte Carla simulation analysis by Coutts and his colleagues suggested 
that the INH-related hepatotoxicity risk might minimize by adopting different dosing strategies according to 
acetylator status. Interestingly, with the current standard dosage of 5 mg /kg/day, the estimated risk is very low 
among rapid acetylators, but rises to 50% among slow acetylators [21]. Although INH-induced hepatotoxicity 
was at first considered idiosyncratic, subsequent studies documented to dose-dependent effect due to the 
accumulation of toxic metabolites [29]. Cojutti and his colleagues seem to support this relationship as 
significantly higher INH exposure observed among patients who experienced hepatotoxicity than among those 
who did not [21]. Hepatotoxicity occurs at a greater frequency when INH and RMP are co-administered than 
International Journal of Sciences: Basic and Applied Research (IJSBAR) (2017) Volume 33, No  1, pp 313-322 
320 
 
when either drug is given alone [7, 30].  Rifampicin induces the metabolism of INH to form hepatotoxic 
hydrazine metabolites and on the other, increased plasma RMP levels may occur due to the displacement of the 
drug from plasma protein binding sites by INH. This pharmacokinetic interaction between the two drugs may 
explain their added toxicity [31]. As described above, we are aware that this study has some limitations. Firstly,  
the potential role that RMP and PZA might have had in contributing to hepatotoxicity development were not 
assessed. Rifampicin may induce hepatocellular type liver damage as INH. Pyrazinamide is known as a dose-
dependent hepatotoxin and causes hepatocellular injury like INH. However, little is known about the risk factors 
and genetic predisposition of PZA or RMP-induced hepatotoxicity, because most studies were undertaken with 
the combination therapy of anti-TB agents as also shown in this study [5].  Measuring the plasma INH, PZA, 
and total RMP levels, being a better predictor for the subsequent development of DIH later during treatment. 
Secondly, if raw data on all subjects had been available and adjustment by other covariants, including 
environmental factors and other gene polymorphisms took into account, the results of this study would have 
been more accurate.  
5. Conclusion 
In conclusion, this study showed that slow acetylator status of NAT2 was a significant susceptibility risk factor 
for anti-TB DIH in Indonesia. The even further research was needed, we proposed here that NAT2 genotyping 
which lead to individually designed doses of INH based on NAT2 genetic information would be possible and 
may be a useful tool in order to to achieve the greatest success outcome for each patient in future. 
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